GLAND vs GRANULES: Stock Comparison

GLAND PHARMA vs GRANULES INDIAUpdated 11 Sept 26, 4:08 PM ISTNSE & company filings

GLAND PHARMA is the larger company by market capitalisation. GLAND PHARMA shows a higher ROE, a higher dividend yield and lower leverage, while GRANULES INDIA shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

GLAND leads 8; GRANULES leads 5 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

GLANDGRANULES

Valuation lens

What price are you paying?

Market CapContext only
₹48,333 Cr
₹22,541 Cr
P/E RatioGRANULES has the lower reading
42.78x
33.73x
P/B RatioGRANULES has the lower reading
4.66x
4.43x
EPSGLAND has the higher reading
₹22.09
₹7.26
Book ValueContext only
₹627.91
₹205.21
Dividend YieldGLAND has the higher reading
0.68%
0.19%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
GLAND is the larger company
₹48,333 Cr vs ₹22,541 Cr
P/E Ratio
GRANULES has a lower P/E
33.73x vs 42.78x
P/B Ratio
GRANULES has a lower P/B
4.43x vs 4.66x
EPS
GLAND has higher earnings per share
₹22.09 vs ₹7.26
Dividend Yield
GLAND has a higher dividend yield
0.68% vs 0.19%
Revenue Growth (TTM YoY)
GRANULES has faster revenue growth
22.8% vs 22.3%
EPS Growth (TTM YoY)
GLAND has faster EPS growth
96.4% vs 31.3%
Qtr Sales Growth
GRANULES has stronger quarterly sales growth
84.16% vs -28.53%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricGLANDGRANULES
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricGLANDGRANULES
Live Price₹2,922.3₹909.3
Day Change-0.83%1.12%
Volume3.89 L78.51 L
52-Week High₹3,042₹910
52-Week Low₹1,573.6₹510.55
Distance from 52W High-3.93%-0.08%

Valuation

MetricGLANDGRANULES
Market Cap₹48,333 Cr₹22,541 Cr
P/E Ratio42.78x33.73x
P/B Ratio4.66x4.43x
EPS₹22.09₹7.26
Book Value₹627.91₹205.21
Dividend Yield0.68%0.19%

Growth

MetricGLANDGRANULES
Revenue Growth (TTM YoY)22.3%22.8%
EPS Growth (TTM YoY)96.4%31.3%
Qtr Sales Growth-28.53%84.16%
Qtr Profit Growth14.96%150.83%

Profitability & Leverage

MetricGLANDGRANULES
ROE12.02%9.11%
ROCE17.2%9.07%
Net Margin16.18%11.15%
Operating Margin38.8%17.19%
Debt to Equity0x0.17x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricGLANDGRANULES
Promoter Holding51.77%37.67%
FII Holding8.74% 1.44 pp17.5% 2.19 pp
DII Holding30.44% 2.91 pp16.11% 0.9 pp
Public Holding9.05% 1.53 pp28.38% 1.28 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GLAND PHARMA and GRANULES INDIA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.